Avience Biomedicals IPO: A Two-Year-Old SME Worth Watching?

Avience Biomedicals IPO: A Two-Year-Old SME Worth Watching?

Reviewed by Team BuyUnlistedShares Research Desk

Last Updated: June 2026

The Indian SME IPO market has produced some remarkable success stories over the past few years. But it has also reminded investors that rapid growth and investment quality are not always the same thing.

That brings us to Avience Biomedicals Limited, a diagnostics and medical-device company that has launched a ₹30.24 crore IPO on the NSE SME platform.

At first glance, the numbers look impressive. Revenue has nearly doubled in a year. Profit has more than tripled. Return ratios appear strong. The healthcare diagnostics sector itself continues to benefit from rising healthcare awareness and increasing testing demand across India.

Yet there is another fact investors should not ignore: the company is barely two years old.

So, does Avience Biomedicals represent an exciting early-stage opportunity, or is it a case where investors need to proceed with extra caution?

Let us break it down.

Understanding the Business

Avience Biomedicals Limited is a Noida-based manufacturer of in-vitro diagnostic (IVD) products and medical devices.

The company was incorporated in June 2024 and operates in the healthcare diagnostics ecosystem by manufacturing and supplying products used by hospitals, laboratories, diagnostic centres, and research institutions.

Its product portfolio includes:

· Rapid diagnostic test kits

· Viral transport media

· Serology reagents

· Biochemistry reagents

· Hematology analysers

· Oxygen concentrators

· Various diagnostic consumables and medical devices

Beyond manufacturing its own products, the company also distributes certain third-party medical equipment, allowing it to broaden its offerings and serve a larger customer base.

The business primarily operates in the B2B and B2G segments, supplying products to healthcare institutions rather than directly to retail consumers.

To support future growth, Avience is also planning a new manufacturing facility within the YEIDA Medical Device Park, which forms one of the major objectives of the IPO.

Why the Diagnostics Sector Matters

Healthcare diagnostics has become one of India's fastest-growing healthcare segments.

The pandemic accelerated awareness around testing and preventive healthcare, while rising healthcare spending, expanding insurance coverage, and increasing healthcare infrastructure continue to support long-term demand.

Diagnostic testing is now deeply embedded in routine healthcare management. Whether it is blood tests, infectious disease detection, pathology screening, or preventive health check-ups, demand for diagnostic products continues to expand.

This broader industry tailwind provides a supportive backdrop for companies operating in the space.

However, sector growth alone does not automatically translate into investment success. The quality of execution matters just as much.

Financial Performance: The Numbers Look Strong

One of the biggest reasons Avience Biomedicals has attracted attention is its recent financial growth.

Revenue Growth

The company reported:

· FY24 Revenue: ₹24.37 crore

· FY25 Revenue: ₹45.97 crore

This represents nearly 89% growth in just one year. For a small company, that is a substantial increase and suggests strong demand for its products and services.

Profitability

The profit growth is even more striking.

· FY24 Profit After Tax: ₹2.14 crore

· FY25 Profit After Tax: ₹7.23 crore

That means profit more than tripled within a year. Such growth naturally attracts investor attention because it suggests the company is scaling faster than its costs.

Return Ratios

The company has also reported strong return metrics, including Return on Net Worth (RoNW) in the high-40% range.

High return ratios generally indicate that management is generating substantial profits relative to shareholder capital. For a growing SME, these figures are undoubtedly encouraging.

The Biggest Caveat: Limited Operating History

While the growth numbers are attractive, Avience Biomedicals has an extremely short financial history.

The company was incorporated in June 2024, meaning investors currently have only about two years of audited financial information available.

That creates several challenges:

Growth Sustainability Is Unproven

A single year of exceptional growth does not automatically establish a long-term trend. Many businesses experience temporary spikes due to:

· Large one-time contracts

· Industry-specific events

· Inventory cycles

· Exceptional market conditions

With only two years of data, it becomes difficult to determine whether current growth rates can continue.

Limited Historical Benchmarking

Established businesses allow investors to study performance across different economic cycles. With Avience, that historical context simply does not exist yet.

Valuation Comparison Is Difficult

There is currently no closely comparable listed company of similar size and business structure. Without direct peers, investors face greater uncertainty when evaluating whether the IPO pricing is attractive.

IPO Details at a Glance

Here are the key details of the issue:

One important point is that this is a pure fresh issue.

Unlike IPOs that contain an Offer for Sale (OFS), none of the existing shareholders are selling shares to the public. Every rupee raised will go directly into the company.

How Will the IPO Proceeds Be Used?

According to the offer documents, the company plans to utilise the IPO proceeds for:

New Manufacturing Facility

A portion of the funds will be used to establish a new manufacturing unit, helping expand production capacity.

Working Capital Requirements

Growing businesses often require additional funds to purchase inventory, manage receivables, and support day-to-day operations. Working capital remains a major focus area.

General Corporate Purposes

The remaining proceeds will support broader business requirements and future growth initiatives.

The High Minimum Investment

One characteristic that often surprises new investors is the minimum application amount.

Because Avience is an SME IPO, the lot size is substantially larger than what investors typically see in mainboard IPOs.

Lot Size

· 600 shares per lot

· Retail minimum: 2 lots

· Total minimum application: 1,200 shares

At the upper price band of ₹208, the minimum investment works out to approximately ₹2.5 lakh.

That is dramatically higher than a typical mainboard IPO application, which often requires only ₹15,000–₹20,000.

This large ticket size is one reason SME IPOs tend to attract a more specialised investor base.

Understanding SME Liquidity Risk

One of the most overlooked risks in SME IPOs is liquidity.

Liquidity simply refers to how easily investors can buy or sell shares.

Mainboard companies often have:

· Thousands of daily buyers and sellers

· Large trading volumes

· Narrow bid-ask spreads

SME-listed companies generally experience:

· Lower trading activity

· Fewer participants

· Wider price spreads

· More difficult exits

This does not necessarily mean the stock will perform poorly.

It simply means investors must recognise that entering a position may be easier than exiting one.

Liquidity risk is often as important as business risk in SME investing.

Key Risks Investors Should Understand

Before considering any SME IPO, investors should understand the major risks involved.

Short Track Record

The company's operating history remains limited.

Growth May Moderate

Exceptional growth rates are difficult to sustain indefinitely.

SME Liquidity Constraints

Post-listing trading activity may be relatively low.

Customer and Supplier Concentration

Dependence on specific customers or suppliers can create operational risks.

Import Dependency

Reliance on imported components and materials can expose the business to currency fluctuations and supply-chain disruptions.

High Capital Commitment

The minimum investment size increases concentration risk for retail investors.

What Should Investors Take Away?

Avience Biomedicals presents an interesting combination of opportunity and uncertainty.

On one hand:

· The company operates in a growing healthcare segment.

· Revenue growth has been strong.

· Profitability has improved significantly.

· The IPO proceeds are intended for business expansion.

On the other hand:

· The operating history is extremely short.

· Valuation benchmarking is difficult.

· SME liquidity risks remain meaningful.

· The minimum investment size is substantial.

Perhaps the most balanced way to view the company is this:

The growth story is real. The risks are real too. Investors should evaluate both with equal seriousness. The strongest takeaway is not whether the IPO is "good" or "bad," but rather that SME investing requires a higher level of due diligence than many investors realise.

Before forming any opinion, reading the Red Herring Prospectus (RHP), understanding the risk factors, and evaluating personal risk tolerance remain essential steps.

Disclaimer

This is written for educational and informational purposes only. Nothing here constitutes investment advice or a recommendation to buy or sell securities. All data is sourced from publicly available information. Investments in securities markets are subject to market risks — please read all offer documents carefully before investing.